Skip to main content

Advertisement

SpringerLink
Log in

A dose-finding and pharmacokinetic study of nedaplatin in elderly patients with advanced non-small cell lung cancer

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

Nedaplatin is a second-generation platinum showing favorable activity against non-small cell lung cancer (NSCLC). Dose-limiting toxicity (DLT) is thrombocytopenia, predicted by creatinine clearance (Ccr). This study was conducted to determine the recommended dose, and evaluate the toxicities, pharmacokinetics and efficacy for elderly NSCLC patients.

Methods

Patients ≥70 years were stratified into two groups based on renal functions: Group A, Ccr ≥ 60 and Group B, 40 ≤ Ccr < 60. The initial doses were 80 and 60 mg/m2 in Groups A and B, respectively. The doses were escalated in 20-mg/m2 increments to 100 mg/m2 until DLT.

Results

Chemotherapy-naïve 39 elderly patients (Group A/Group B: 22/17) received a total of 83 cycles. Major toxicities were hematological. In Group A, one of the 15 patients at 100 mg/m2 experienced DLT (neutropenia) and the recommended dose was determined at 100 mg/m2. In Group B, three of the five patients had DLTs (leukopenia, neutropenia, thrombocytopenia and febrile neutropenia) at 100 mg/m2, and the recommended dose was determined at 80 mg/m2. The percentage decreases of neutrophil were well correlated with total and free-Pt AUCs. Partial responses were observed in 13 (33%) of the 39 patients, and 12 of the 13 patients who responded had a squamous cell carcinoma.

Conclusions

Nedaplatin was administered simply and feasibly by stratifying renal function and exerted favorable antitumor activity for elderly patients with NSCLC, especially on squamous cell carcinoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Kaneko S, Ishikawa KB, Yoshimi I et al (2003) Projection of lung cancer mortality in Japan. Cancer Sci 94:919–923

    Article  PubMed  CAS  Google Scholar 

  2. Schiller JH, Harrington D, Belani CP et al (2002) Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 346:92–98

    Article  PubMed  CAS  Google Scholar 

  3. Ohe Y, Ohashi Y, Kubota K et al (2007) Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol 18:317–323

    Article  PubMed  CAS  Google Scholar 

  4. Kubota K, Watanabe K, Kunitoh H et al (2004) Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small cell lung cancer: the Japanese Taxotere Lung Cancer Study Group. J Clin Oncol 22:254–261

    Article  PubMed  CAS  Google Scholar 

  5. Oshita F, Kurata T, Kasai T et al (1995) Prospective evaluation of the feasibility of cisplatin-based chemotherapy for elderly lung cancer patients with normal organ functions. Jpn J Cancer Res 86:1198–1202

    PubMed  CAS  Google Scholar 

  6. Yamamoto N, Tamura T, Maeda M et al (1995) The influence of ageing on cisplatin pharmacokinetics in lung cancer patients with normal organ function. Cancer Chemother Pharmacol 36:102–106

    Article  PubMed  CAS  Google Scholar 

  7. Kanzawa F, Matsushima Y, Nakano H et al (1988) Antitumor activity of a new platinum compound (glycolate-O,O′) diammineplatinum (II) (254-S), against non-small cell lung carcinoma grown in a human tumor clonogenic assay system. Anticancer Res 8:323–327

    PubMed  CAS  Google Scholar 

  8. Suzumura Y, Kato T, Ueda R et al (1989) Effect of treatment schedule on antitumor activity of glycolate-0, 0′-diammineplatinum(II), a new platinum derivative: comparison with cis-diamminedichloroplatinum(II). Anticancer Res 9:1083–1088

    PubMed  CAS  Google Scholar 

  9. Hida S, Okada K, Yoshida O (1990) Advantages in combination chemotherapy using cisplatin and its analogues for human testicular tumor xenografts. Jpn J Cancer Res 81:425–430

    PubMed  CAS  Google Scholar 

  10. Furuse K, Fukuoka M, Kurita Y et al (1992) A phase II clinical study of cis-diammine glycolato platinum, 254-S, for primary lung cancer. Gan To Kagaku Ryoho 19:879–884

    PubMed  CAS  Google Scholar 

  11. Sasaki Y, Fukuda M, Morita M et al (1990) Prediction from creatinine clearance of thrombocytopenia and recommended dose in patients receiving (glycolato-O,O′)-diammine platinum (II) (NSC 375101D). Jpn J Cancer Res 81:196–200

    PubMed  CAS  Google Scholar 

  12. LeRoy AF, Wehling ML, Sponseller HL et al (1977) Analysis of platinum in biological materials by flameless atomic absorption spectrophotometry. Biochem Med 18:184–191

    Article  PubMed  CAS  Google Scholar 

  13. Yamaoka K, Nakagawa T, Uno T (1978) Application of Akaike’s information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm 6:165–175

    Article  PubMed  CAS  Google Scholar 

  14. Sasaki Y, Tamura T, Eguchi K et al (1989) Pharmacokinetics of (glycolate-O,O′)-diammine platinum (II), a new platinum derivative, in comparison with cisplatin and carboplatin. Cancer Chemother Pharmacol 23:243–246

    Article  PubMed  CAS  Google Scholar 

  15. The Elderly Lung Cancer Vinorelbine Italian Study Group (1999) Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small cell lung cancer: The Elderly Lung Cancer Vinorelbine Italian Study Group. J Natl Cancer Inst 91:66–72

    Article  Google Scholar 

  16. Gridelli C, Perrone F, Gallo C et al (2003) Chemotherapy for elderly patients with advanced non-small cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 95:362–372

    Article  PubMed  CAS  Google Scholar 

  17. Kudoh S, Takeda K, Nakagawa K et al (2006) Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small cell lung cancer: results of the West Japan Thoracic Oncology Group trial (WJTOG 9904). J Clin Oncol 24:3657–3663

    Article  PubMed  CAS  Google Scholar 

  18. Calvert AH, Newell DR, Gumbrell LA et al (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748–1756

    PubMed  CAS  Google Scholar 

  19. Kato H, Fukuchi M, Manda R et al (2003) Efficacy and toxicity of nedaplatin and 5-FU with radiation treatment for advanced esophageal carcinomas. Anticancer Res 23:3493–3498

    PubMed  CAS  Google Scholar 

  20. Kodaira T, Fuwa N, Tachibana H et al (2006) Phase I study of S-1 and nedaplatin for patients with recurrence of head and neck cancer. Anticancer Res 26:2265–2268

    PubMed  CAS  Google Scholar 

  21. Yoshioka T, Sakayori M, Kato S et al (2006) Dose escalation study of docetaxel and nedaplatin in patients with relapsed or refractory squamous cell carcinoma of the esophagus pretreated using cisplatin, 5-fluorouracil, and radiation. Int J Clin Oncol 11:454–460

    Article  PubMed  CAS  Google Scholar 

  22. Kanai M, Matsumoto S, Nishimura T et al (2007) Retrospective analysis of 27 consecutive patients treated with docetaxel/nedaplatin combination therapy as a second-line regimen for advanced esophageal cancer. Int J Clin Oncol 12:224–227

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This work was supported by a Grant-in-Aid for Cancer Research (9-25) from the Ministry of Health and Welfare, Tokyo, Japan.

Author information

Authors and Affiliations

  1. Division of Internal Medicine, National Cancer Center Hospital, 5-1-1, Tsukiji Chuo-ku, Tokyo, 104-0045, Japan

    Noboru Yamamoto, Tomohide Tamura, Ikuo Sekine, Hideo Kunitoh & Yuichiro Ohe

  2. Cancer Chemotherapy Center, Osaka Medical College, Osaka, Japan

    Takayasu Kurata

  3. Division of Thoracic Oncology, Shizuoka Cancer Center Hospital, Shizuoka, Japan

    Nobuyuki Yamamoto

  4. National Cancer Center Hospital East, Kashiwa, Japan

    Nagahiro Saijo

Authors
  1. Noboru Yamamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tomohide Tamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Takayasu Kurata
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nobuyuki Yamamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ikuo Sekine
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hideo Kunitoh
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yuichiro Ohe
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Nagahiro Saijo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Noboru Yamamoto.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yamamoto, N., Tamura, T., Kurata, T. et al. A dose-finding and pharmacokinetic study of nedaplatin in elderly patients with advanced non-small cell lung cancer. Cancer Chemother Pharmacol 65, 79–88 (2009). https://doi.org/10.1007/s00280-009-1006-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-009-1006-9

Keywords

Search

Navigation